Unichem Laboratories gets USFDA nod for Metronidazole tablets

Unichem Laboratories has received approval from the US Food & Drug Administration to sell generic Metronidazole tablets, an anti-infective agent, in the American market.

The approval is for Metronidazole in strengths of 250 mg and 500 mg, which are therapeutically equivalent to Flagyl Tablets of corresponding strengths of GD Searle LLC, the company said in a filing to the BSE.

The drug is an anti-infective agent used to treat a variety of bacterial and protozoal infections.

The product will be commercialised from Unichem's Ghaziabad plant. Active pharmaceutical ingredient Metronidazole used for this ANDA is also made in-house at Roha plant, it said.

At present, around six other companies have generic approvals for the US market and the estimated market size is over $100 million, the company added.

Shares of Unichem Laboratories were trading at Rs 216 per scrip in the afternoon trade, up 0.87 per cent from the previous close, on the BSE.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • FDI in insurance must be allowed with a rider to increase penetration

    The Union cabinet has cleared the proposal to raise foreign direct investment (FDI) in the insurance sector through the FIPB route from the current 26

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Varun Dutt

Which is safer? Flying or driving?

The recent tragedies involving the Taiwan’s TransAsia Airways flight, and ...

Parvez Imam

Revisiting history can do us all good

We often think that we understand history. We read it ...

Bubbles Sabharwal

Your happiness doesn’t depend on your needs

They are two different words (and even worlds) altogether: having ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture